이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Eli Lilly 관리

관리 기준 확인 2/4

Eli Lilly's CEO는 Dave Ricks, Jan2017 에 임명되었습니다 의 임기는 7.58 년입니다. 총 연간 보상은 $ 26.57M, 6.1% 로 구성됩니다. 6.1% 급여 및 93.9% 보너스(회사 주식 및 옵션 포함). 는 ARS 597.87B 가치에 해당하는 회사 주식의 0.076% 직접 소유합니다. 597.87B. 경영진과 이사회의 평균 재임 기간은 각각 5.9 년과 9.7 년입니다.

주요 정보

Dave Ricks

최고 경영자

US$26.6m

총 보상

CEO 급여 비율	6.1%
CEO 임기	7.7yrs
CEO 소유권	0.07%
경영진 평균 재임 기간	6yrs
이사회 평균 재임 기간	8.3yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Dave Ricks 의 보수는 Eli Lilly 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	US$7b
Mar 31 2024	n/a	n/a	US$6b
Dec 31 2023	US$27m	US$2m	US$5b
Sep 30 2023	n/a	n/a	US$5b
Jun 30 2023	n/a	n/a	US$6b
Mar 31 2023	n/a	n/a	US$6b
Dec 31 2022	US$21m	US$2m	US$6b
Sep 30 2022	n/a	n/a	US$6b
Jun 30 2022	n/a	n/a	US$6b
Mar 31 2022	n/a	n/a	US$6b
Dec 31 2021	US$22m	US$2m	US$6b
Sep 30 2021	n/a	n/a	US$6b
Jun 30 2021	n/a	n/a	US$6b
Mar 31 2021	n/a	n/a	US$6b
Dec 31 2020	US$24m	US$1m	US$6b
Sep 30 2020	n/a	n/a	US$6b
Jun 30 2020	n/a	n/a	US$6b
Mar 31 2020	n/a	n/a	US$6b
Dec 31 2019	US$21m	US$1m	US$5b
Sep 30 2019	n/a	n/a	US$4b
Jun 30 2019	n/a	n/a	US$4b
Mar 31 2019	n/a	n/a	US$3b
Dec 31 2018	US$17m	US$1m	US$3b
Sep 30 2018	n/a	n/a	US$372m
Jun 30 2018	n/a	n/a	-US$166m
Mar 31 2018	n/a	n/a	US$1b
Dec 31 2017	US$16m	US$1m	-US$86m

보상 대 시장: Dave 의 총 보상 ($USD 26.57M )은 AR 시장( $USD 6.09M ).

보상과 수익: Dave 의 보상은 지난 1년 동안 20% 이상 증가했습니다.

CEO

Dave Ricks (56 yo)

7.7yrs

테뉴어

US$26,565,732

보상

Mr. David A. Ricks, also known as Dave, has been a Director of Adobe Inc. since April 12, 2018 and previously served as its Director since June 2017. He served as a Director of Elanco Animal Health Incorpo...

리더십 팀

이름	위치	테뉴어	보상	소유권
David Ricks	Chairman	7.7yrs	US$26.57m	0.067% $ 541.1b
Daniel Skovronsky	EVP, Chief Scientific Officer and President of Lilly Research Laboratories & Lilly immunology	6.3yrs	US$11.85m	0.021% $ 173.0b
Anat Hakim	Executive VP	4.6yrs	US$7.01m	0.0034% $ 27.2b
Jacob Van Naarden	Executive VP & President of Loxo	no data	US$4.89m	0.0023% $ 18.4b
Lucas Montarce	Executive VP & CFO	no data	데이터 없음	0.0012% $ 9.3b
Donald Zakrowski	Senior VP of Finance & Chief Accounting Officer	11.8yrs	데이터 없음	0.00090% $ 7.2b
Diogo Rau	EVP & Chief Information and Digital Officer	3.3yrs	US$5.10m	0.0012% $ 9.9b
Alonzo Weems	EVP of Enterprise Risk Management and Chief Ethics & Compliance Officer	3.3yrs	데이터 없음	0.00088% $ 7.1b
Eric Dozier	Executive Vice President of Human Resources & Diversity	1.8yrs	데이터 없음	0.00083% $ 6.7b
Jeffrey Simmons	Senior VP & President of Elanco Animal Health	16.7yrs	US$5.38m	데이터 없음
W. Moody	SVP of Global Active Pharmaceutical Ingredient	8.1yrs	데이터 없음	데이터 없음
Anne White	EVP & President of Lilly Neuroscience	6yrs	데이터 없음	0.0073% $ 58.6b

6.0yrs

평균 재임 기간

54yo

평균 연령

경험이 풍부한 관리: LLY 의 관리팀은 노련하고 경험 (평균 재직 기간 5.9 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
David Ricks	Chairman	7.7yrs	US$26.57m	0.067% $ 541.1b
Gabrielle Greene-Sulzberger	Independent Director	3.7yrs	US$335.50k	데이터 없음
Sidney Taurel	Chairman Emeritus	15.7yrs	US$13.06m	데이터 없음
Jon Erik Fyrwald	Independent Director	18.8yrs	US$344.88k	0.000010% $ 80.5m
Ralph Alvarez	Independent Director	15.4yrs	US$336.00k	0.000080% $ 644.1m
William Kaelin	Independent Director	12.3yrs	US$349.15k	데이터 없음
Mary Hedley	Independent Director	2.3yrs	US$319.00k	0.000040% $ 322.0m
Juan Luciano	Lead Independent Director	8.6yrs	US$373.00k	데이터 없음
Katherine Baicker	Independent Director	12.8yrs	US$336.00k	데이터 없음
Jamere Jackson	Independent Director	7.9yrs	US$345.00k	데이터 없음
Karen Walker	Independent Director	5.8yrs	US$359.00k	데이터 없음
Kimberly Johnson	Independent Director	3.6yrs	US$316.00k	데이터 없음

8.3yrs

평균 재임 기간

62.5yo

평균 연령

경험이 풍부한 이사회: LLY 의 이사회는 경험(평균 재직 기간 9.7 년)으로 간주됩니다.

Eli Lilly 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Eli Lilly and Co. Appoints Lucas Montarce as CFO

Eli Lilly and Company Announces Retirement of Marschall S. Runge as Independent Director, Effective August 31, 2024

Eli Lilly and Company Announces Resignation of Anat Ashkenazi as Chief Financial Officer, Effective July 2024

Eli Lilly and Company Appoints Melissa Seymour as Executive Vice President of Global Quality and Member of the Executive Committee, Effective July 22, 2024

Eli Lilly and Company Announces Retirement of Alonzo Weems, Executive Vice President of Enterprise Risk Management and Chief Ethics and Compliance Officer, Effective December 31, 2024

Philip Johnson to Retire as Eli Lilly and Company's Treasurer

Recent updates

FDA Approves Lilly's EBGLYSS (Lebrikizumab-Lbkz) for Adults and Children 12 Years and Older with Moderate-To-Severe Atopic Dermatitis

Eli Lilly and Co. Appoints Lucas Montarce as CFO

Eli Lilly and Company Announces Positive Topline Results from the QWINT-1 and QWINT-3 Phase 3 Clinical Trials Evaluating Once Weekly Insulin Efsitora Alfa

Eli Lilly and Company Announces Positive Topline Results from the Surmount-1 Three-Year Study Evaluating the Efficacy and Safety of Tirzepatide

Eli Lilly and Company Announces Retirement of Marschall S. Runge as Independent Director, Effective August 31, 2024

Eli Lilly and Company (NYSE:LLY) completed the acquisition of Morphic Holding, Inc. (NasdaqGM:MORF) from TAS Partners, LLC, Timothy Springer, Chafen Lu and others.

Eli Lilly and Company Raises Earnings Guidance Full-Year 2024

Eli Lilly and Company to Report Q2, 2024 Results on Aug 08, 2024

Eli Lilly and Company (NYSE:LLY) entered into an agreement and plan of merger to acquire Morphic Holding, Inc. (NasdaqGM:MORF) from TAS Partners, LLC, Timothy Springer, Chafen Lu and others for $3.2 billion.

Eli Lilly and Company(NYSE:LLY) dropped from Russell 1000 Growth-Defensive Index

Eli Lilly and Company Declares Dividend for the Third Quarter of 2024, Payable on September 10, 2024

Eli Lilly and Company Announces Detailed Results from the Surmount-OSA Phase 3 Clinical Trials Evaluating Tirzepatide Injection

Eli Lilly and Company Announces Resignation of Anat Ashkenazi as Chief Financial Officer, Effective July 2024

Eli Lilly and Company Appoints Melissa Seymour as Executive Vice President of Global Quality and Member of the Executive Committee, Effective July 22, 2024

Eli Lilly and Company Announces Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO® Annual Meeting

Eli Lilly and Company Announces Positive Topline Results from the Qwint-2 and Qwint-4 Phase 3 Clinical Trials Evaluating Once-Week Dosing

Eli Lilly and Company Announces Retirement of Alonzo Weems, Executive Vice President of Enterprise Risk Management and Chief Ethics and Compliance Officer, Effective December 31, 2024

Eli Lilly and Company Declares Dividend for the Second Quarter of 2024, Payable on June 10, 2024

Eli Lilly and Company Raises Earnings Guidance for the Year 2024

Eli Lilly and Company Raises Earnings Guidance for the Year 2024

Eli Lilly and Company to Report Q1, 2024 Results on Apr 30, 2024

As You Sow Files an Exempt Solicitation Statement and Request Vote for the Proposal

SEIU Benefit Plans Master Trust Files a Notice of Exempt Solicitation to Eli Lilly and Company

Eli Lilly and Company Announces Results from A First-Of-Its-Kind Study of Lebrikizumab

Eli Lilly and Company to Present Donanemab in Early Symptomatic Alzheimer's Disease

Philip Johnson to Retire as Eli Lilly and Company's Treasurer

Eli Lilly and Company Provides Earnings Guidance for the Fiscal Year 2024

Johna Norton to Retire as Lilly Executive Vice President of Global Quality

Eli Lilly and Company to Report Q4, 2023 Results on Feb 06, 2024

Eli Lilly and Company Launches End-To-End Digital Healthcare Experience Through LillyDirect

Eli Lilly and Company (NYSE:LLY) completed the acquisition of POINT Biopharma Global Inc. (NasdaqCM:PNT) from Joe A. McCann, Allan Charles Silber, Neil E. Fleshner and others.

Eli Lilly and Company Announces Updated Clinical Data from the International Phase 1/2 Study of Pirtobrutinib in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

Eli Lilly and Company Declares Dividend for the First Quarter of 2024, Payable on March 8, 2024

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령